Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 3, 2026International Journal of HematologyOpen Access

Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan

View Full Paper
Ask AI
Bookmark
Share

Authors

NTNaoto TakahashiSKShinya KimuraEMEri Matsuki

Discussion

Loading...

Member takes

Overview

Observational study evaluates TFR success in CML patients, highlighting deep molecular response as critical.

Key Points

  • This study aims to assess long-term treatment-free remission outcomes in chronic myeloid leukemia patients after discontinuing tyrosine kinase inhibitors.
  • Large observational study with 795 eligible patients
  • Included both prospective (283) and retrospective (512) cohorts
  • Median follow-up of 32 months post-TKI discontinuation
  • Analyzed predictors of successful treatment-free remission
  • Five-year treatment-free remission rate is 65.2%
  • 99% of patients who relapsed regained a major molecular response upon resuming TKI therapy
  • Duration of deep molecular response was a key predictor; each additional year reduced relapse risk by 12.5%
  • 41% success rate in second treatment-free remission attempts among 32 patients

Cite This Study

Takahashi et al. (2026) studied this question.

synapsesocial.com/papers/69a67efaf353c071a6f0abb6https://doi.org/10.1007/s12185-026-04184-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 12025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia2025 · 126 citations
  2. 2Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia2017 · 111 citations
  3. 3Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial2021 · 89 citations
  4. 4Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan2018 · 79 citations
  5. 5Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease2013 · 417 citations